Looking at the periphery-new hypothesis to look for new targets for Alzheimer’s disease therapy
Jesús Avila , Mar Pérez , Marina Avila-Villanueva , Ismael Santa-María , Félix Hernández
Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (3) : 151 -163.
Currently, the predominant targets for the treatment of Alzheimer’s disease (AD) are the main components of the two pathological structures: senile plaques (composed of amyloid beta peptide aggregates) or neurofibrillary tangles (constructed of tau protein polymers). However, the existence of adequate disease modifiers based on such targets is discussed. In this special issue, it has been suggested to search for new possible targets for AD therapy. This contribution tries to analyze non-neuronal tissues (periphery) to identify potential factors (target) involved in the development of AD.
Alzheimer’s disease / non-neuronal tissues / biomarkers
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
Davies P. Challenging the cholinergic hypothesis in Alzheimer disease. JAMA. 1999; 281: 1433-4. |
| [9] |
|
| [10] |
Zhu X, Raina AK, Perry G, Smith MA. Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol. 2004; 3: 219-26. |
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
Liang W, Chen Q, Cheng S, Wei R, Li Y, Yao C, |
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002; 58: 1791-800. |
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
Guo Q, Li H, |
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
Cardiogenic dementia. Lancet. 1977; 309: 27-8. |
| [41] |
SPRINT MIND Investigators for the SPRINT Research Group; |
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
Nho K, Kueider-Paisley A, Ahmad S, MahmoudianDehkordi S, Arnold M, |
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
Stocker H, Beyer L, Trares K, Perna L, Rujescu D, Holleczek B, |
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI). The Alzheimer Precision Medicine Initiative. J Alzheimers Dis. 2019; 68: 1-24. |
/
| 〈 |
|
〉 |